Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06945458 · ClinicalTrials.gov registry record · Phase 1

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

A Phase 1 study of Atopic Dermatitis, sponsored by Kymera Therapeutics.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
12
Study locations

NCT06945458 is a Phase 1 study of Atopic Dermatitis that has completed, run by Kymera Therapeutics. The registered enrollment target is 22 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower). The trial reports 12 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06945458, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by Kymera Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
12
Study locations

Study Summary

This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG KT-621

Study Locations (12)

Florida

  • Kymera Investigative Site - Boynton Beach
  • Kymera Investigative Site - Hollywood
  • Kymera Investigative Site - Tampa

California

  • Kymera Investigative Site - Fountain Valley
  • Kymera Investigative Site - Santa Monica

Ohio

  • Kymera Investigative Site - Dublin
  • Kymera Investigative Site - Springfield

Alabama

  • Kymera Investigative Site - Birmingham

North Dakota

  • Kymera Investigative Site - Fargo

Oklahoma

  • Kymera Investigative Site - Tulsa

South Carolina

  • Kymera Investigative Site - Charleston

Texas

  • Kymera Investigative Site - San Antonio

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2025-04-17
Est. Completion 2025-11-10
Phase Phase 1

Sponsor

Kymera Therapeutics

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06945458

The ClinicalTrials.gov registry entry for NCT06945458 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower). The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which KT-621 is the first listed.

NCT06945458 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Ohio.

Frequently Asked Questions

What is clinical trial NCT06945458 about?

NCT06945458 is a clinical study titled "Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)". This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).

What is the current status of trial NCT06945458?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2025-04-17. Estimated completion is 2025-11-10.

What conditions does trial NCT06945458 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT06945458?

The interventions under investigation include: KT-621 (DRUG).

Who is sponsoring clinical trial NCT06945458?

This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06945458 being conducted?

This trial has 12 study locations across Alabama, California, Florida, North Dakota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.